Mirum Pharmaceuticals, Inc. (MIRM) closed the last trading session at $49.93, gaining 2.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $63 indicates a 26.2% upside potential.The mean estimate comprises 10 short-term price targets with a standard deviation of $8.30. While the lowest estimate of $50 indicates a 0.1% increase from the current price level, the most optimistic analy ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

Mirum Pharmaceuticals, Inc. (MIRM) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.I ...

Shares of Mirum Pharmaceuticals (MIRM) were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024, along with an encouraging outlook and growth strategy for 2025.Mirum’s commercial portfolio comprises of lead product, Livmarli (maralixibat), which is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progres ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

Mirum Pharmaceuticals: Transforming Lives in Rare Disease J a n u a r y 2 0 2 5 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to managem include all statements other than statements of historical fact contained in this presentation, including information concerning our business strategy, objectives and oppor opportunities for LIVMARLI, CHOLBAM, chenodiol, and Mirum's clinica ...

Core Insights - The Fortune Teller is a team of two analysts with over 30 years of combined market experience [1] - The team includes a former licensed investment advisor with a background in asset management, holding degrees in Accounting & Economics and Computer Sciences, as well as MBAs [1] - They lead the investing group Wheel of Fortune, which shares actionable trading ideas across various asset classes, sectors, and industries [1] Service Features - The service aims to provide a comprehensive resource for investment and portfolio ideas while educating subscribers [1] - It includes the Funds Macro Portfolio, focusing on ETFs and CEFs for less active investors [1] - The Single Macro Portfolio is designed for more active investors, focusing on single equity [1] - Additional offerings include educational content and a live chat room for discussions among investors and The Fortune Teller [1]

Mirum has 3 approved products – LIVMARLI, cholbam and chenodal. LIVMARLI, or maralixibat, is an inhibitor of ileal bile acid transporter, andMirum Pharmaceuticals (NASDAQ: MIRM ) is a liver and rare disease franchise I used to own and cover earlier. I covered it last over a year ago.About the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any t ...

A month has gone by since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM) . Shares have lost about 0.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Mirum Pharmaceuticals due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Mirum's Q3 Earnings & Re ...